Clinical Trial Update: Masitinib in Refractory Active Rheumatoid Arthritis [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for masitinib in refractory active rheumatoid arthritis shows termination after Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Rheumatoid Arthritis (RA) | Phase 2, Phase 3 | Status: TERMINATED